Xencor Inc (XNCR): Total Assets
$875.50M
As of 2025-12-31
$724.96M
As of 2026-06-30
+1.1%
3-year compound annual growth
+4.5%
5-year compound annual growth
+15.5%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $875.50M | -8.0% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $951.95M | -1.4% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $965.13M | +14.0% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $846.27M | +1.0% | 2025-02-24, Balance as of period end |
| 2021-12-31 | $838.21M | +19.2% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $703.24M | +4.9% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $670.25M | +16.2% | 2021-02-24, Balance as of period end |
| 2018-12-31 | $576.73M | +47.8% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $390.20M | -9.0% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $428.56M | +107.1% | 2018-02-28, Balance as of period end |
| 2015-12-31 | $206.91M | +205.1% | 2017-03-01, Balance as of period end |
| 2014-12-31 | $67.82M | -22.3% | 2016-03-08, Balance as of period end |
| 2013-12-31 | $87.31M | n/a | 2015-02-23, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Xencor Inc (XNCR) | 2025-12-31 | $875.50M | -8.0% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $239.34M | -5.8% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $166.13M | +32.5% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $200.46M | -29.8% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $108.42M | -34.1% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $284.73M | +59.8% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $346.53M | -25.2% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $138.29M | +43.5% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $256.85M | -1.8% |
Compare XNCR, LFCR, GYRE, URGN side by side · Screen every company in Pharmaceutical Preparations ↗